IFNγ突变导致CTLA-4抑制剂耐药
IFNγ Mutations Prompt CTLA-4 Inhibitor Resistance.
PubMed 文献 · Cancer Discov · 2016-11-18
一项研究分析16例黑色素瘤患者的全外显子肿瘤测序数据,发现12例伊匹木单抗无应答者存在多个拷贝数改变导致关键IFNγ通路基因缺失。缺乏IFNGR1的黑色素瘤小鼠对抗CTLA-4治疗应答受损,总生存期显著缩短。
要点
- 12例伊匹木单抗无应答的黑色素瘤患者存在IFNγ通路基因拷贝数缺失
- 缺乏IFNGR1的黑色素瘤小鼠对抗CTLA-4治疗应答受损
- 缺乏IFNGR1的黑色素瘤小鼠总生存期显著缩短
核心结论
- IFNγ信号缺失是许多患者对CTLA-4抑制剂伊匹木单抗无应答的原因之一。
研究设计与样本
- 分析16例黑色素瘤患者的全外显子肿瘤测序数据,并使用缺乏IFNGR1的黑色素瘤小鼠模型研究对抗CTLA-4治疗的应答。
主要发现
- 在12例伊匹木单抗无应答者中发现多个拷贝数改变导致关键IFNγ通路基因缺失。
- 携带缺乏IFNGR1肿瘤的小鼠对抗CTLA-4治疗应答受损,且与肿瘤IFNGR1完整的小鼠相比总生存期显著缩短。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A recent study pinpoints loss of IFNγ signaling as one reason why many patients do not respond to the CTLA-4 inhibitor ipilimumab. Analyzing whole-exome tumor sequencing data from 16 patients with melanoma, the researchers found multiple copy-number alterations that led to the loss of key IFNγ pathway genes in 12 ipilimumab nonresponders. Mice bearing melanoma tumors that lacked one of these genes, IFNGR1, also had an impaired response to anti-CTLA-4 therapy and significantly reduced overall survival, compared with their counterparts whose tumors had intact IFNGR1.
来源:Cancer Discov,查看原文。版权归原作者所有。
引用
- IFNγ Mutations Prompt CTLA-4 Inhibitor Resistance. Cancer Discov. 2016. PMID: 27864228. doi:10.1158/2159-8290.CD-NB2016-148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。